Proteomics International Share Prices Declined after the sale of its Shareholding in CPR

Proteomics International Laboratories Ltd

Proteomics International Laboratories Ltd (ASX: PIQ) has announced that it will receive an amount of $928,399 for the sale of its shareholding in CPR Pharma services Pty Ltd. This sale is due on or about 30 September 2018. The memorandum of understanding between proteomics International and CPR remains in place which targets advanced diagnostics and analytical services for clinical trials. In March 2018, Proteomics International issued 3,868,305 ordinary PIQ shares at a deemed issue price of $0.3045 to acquire 10% of the fully diluted issued share capital of CPR. The share, therefore, equates to receipt of $0.24 per PIQ share issued. The issued share will be remained in escrow until 4 March 2019. With this news, the stock price tumbled 1.754% as on 17 November 2018. [optin-monster-shortcode id=”wxhmli4jjedneglg1trq”]

In the Financial year 2018, revenue from the ordinary activities from the company’s analytical services reached $1,176,457 which was a 27% increase from the previous year. Company’s combined income from all sources rose 16% to $2.15m. The loss of $1,440,108 from ordinary activities reflects normal operational costs and non-cash items.

PIQ’s share traded at $0.280 at the market capitalization of 22.83m as on 17 September 2018(AEST 4:47 PM).

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Checkout our Free Dividend Stocks Report

Specially made for income-hungry investors, Invest in growing Franked Dividends an opportunity that should not be missed.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report